AGN 194277 is a synthetic compound classified as an agonist of the adenosine A2A receptor, primarily investigated for its potential therapeutic applications in treating Parkinson's disease and other movement… Read more
AGN 194277 is a synthetic compound classified as an agonist of the adenosine A2A receptor, primarily investigated for its potential therapeutic applications in treating Parkinson's disease and other movement disorders by modulating dopaminergic pathways. Laboratories rely on high-quality reference standards of the parent drug, alongside its specific impurities, to support rigorous pharmaceutical analysis. These compounds are essential for impurity profiling, method validation, and quality control, ensuring that analytical procedures remain accurate during the development and manufacturing process. By utilizing these specialized reference materials in testing protocols such as high-performance liquid chromatography, researchers can reliably monitor product stability and ensure regulatory compliance. The availability of these distinct standards allows for the precise identification and quantification of related substances, which is critical for maintaining the necessary safety and efficacy profiles in pharmaceutical research and development.